Neurodegenerative disorders: Assessing the impact of natural vs drug‐induced treatment options

Neurodegenerative illnesses refer to the gradual, cumulative loss of neural activity. Neurological conditions are considered to be the second leading cause of mortality in the modern world and the two most prevalent ones are Parkinson's disease and Alzheimer's disease. The negative side effects of pharmaceutical use are a major global concern, despite the availability of many different treatments for therapy. We concentrated on different types of neurological problems and their influence on targets, in vitro, in vivo, and in silico methods toward neurological disorders, as well as the molecular approaches influencing the same, in the first half of the review. The bulk of the second half of the review focuses on the many categories of treatment possibilities, including natural and artificial. Nevertheless, herbal treatment solutions are piquing scholarly attention due to their anti‐oxidative properties and accessibility. However, more quality investigations and innovations are undoubtedly needed to back up these conclusions.

[1]  Joong Sun Kim,et al.  Neuroprotective effect of Geijigadaehwang-tang against trimethyltin-induced hippocampal neurodegeneration: An in vitro and in vivo study. , 2022, Journal of ethnopharmacology.

[2]  G. Zyuz’kov,et al.  Targeting cAMP-pathway in Regeneration-Competent Cells of Nervous Tissue: Potential to Create a Novel Drug for Treatment of Ethanol-Induced Neurodegeneration. , 2021, Central nervous system agents in medicinal chemistry.

[3]  Stephen S. Lim,et al.  The burden of neurological disorders across the states of India: the Global Burden of Disease Study 1990–2019 , 2021, The Lancet. Global health.

[4]  S. Lipton,et al.  Protein S-nitrosylation and oxidation contribute to protein misfolding in neurodegeneration. , 2021, Free radical biology & medicine.

[5]  L. Ferraiuolo,et al.  DNA damage as a mechanism of neurodegeneration in ALS and a contributor to astrocyte toxicity , 2021, Cellular and Molecular Life Sciences.

[6]  G. Cestra,et al.  Chemical chaperones targeted to the endoplasmic reticulum (ER) and lysosome prevented neurodegeneration in a C9orf72 repeat expansion drosophila amyotrophic lateral sclerosis (ALS) model , 2021, Pharmacological Reports.

[7]  Paul M. Levine,et al.  O-GlcNAc modification of small heat shock proteins enhances their anti-amyloid chaperone activity , 2021, Nature Chemistry.

[8]  A. Abramov,et al.  Mitochondria and lipid peroxidation in the mechanism of neurodegeneration: Finding ways for prevention , 2020, Medicinal research reviews.

[9]  E. Potapova,et al.  Interaction of Oxidative Stress and Misfolded Proteins in the Mechanism of Neurodegeneration , 2020, Life.

[10]  D. Klenerman,et al.  Insoluble tau aggregates induce neuronal death through modification of membrane ion conductance, activation of voltage‐gated calcium channels and NADPH oxidase , 2020, The FEBS journal.

[11]  John D. Finan,et al.  The Impact of Traumatic Brain Injury on Amyotrophic Lateral Sclerosis - From Bedside to Bench. , 2019, Journal of neurophysiology.

[12]  M. Haque,et al.  Thymoquinone prevents neurodegeneration against MPTP in vivo and modulates α-synuclein aggregation in vitro , 2019, Neurochemistry International.

[13]  M. Faheem,et al.  Neuroprotective effects of melatonin and celecoxib against ethanol-induced neurodegeneration: a computational and pharmacological approach , 2019, Drug design, development and therapy.

[14]  Bing Zhang,et al.  Preparation, optimization and cellular uptake study of tanshinone I nanoemulsion modified with lactoferrin for brain drug delivery , 2019, Pharmaceutical development and technology.

[15]  Jun‐Seok Lee,et al.  Crosstalk between Oxidative Stress and Tauopathy , 2019, International journal of molecular sciences.

[16]  A. Azadi,et al.  Brain Delivery of Curcumin Using Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: Preparation, Optimization, and Pharmacokinetic Evaluation. , 2018, ACS chemical neuroscience.

[17]  Nima Razzaghi-Asl,et al.  The potential of natural product vs neurodegenerative disorders: In silico study of artoflavanocoumarin as BACE-1 inhibitor , 2018, Comput. Biol. Chem..

[18]  B. Lu,et al.  Altered ER–mitochondria contact impacts mitochondria calcium homeostasis and contributes to neurodegeneration in vivo in disease models , 2018, Proceedings of the National Academy of Sciences.

[19]  J. Tamarit,et al.  Iron in Friedreich Ataxia: A Central Role in the Pathophysiology or an Epiphenomenon? , 2018, Pharmaceuticals.

[20]  Honglin Luo,et al.  Enteroviral Infection: The Forgotten Link to Amyotrophic Lateral Sclerosis? , 2018, Front. Mol. Neurosci..

[21]  A. Abramov,et al.  Role of mitochondrial ROS in the brain: from physiology to neurodegeneration , 2018, FEBS letters.

[22]  P. Sil,et al.  Nutraceuticals: An emerging therapeutic approach against the pathogenesis of Alzheimer's disease , 2017, Pharmacological research.

[23]  M. Tomás,et al.  Oxidative stress and the amyloid beta peptide in Alzheimer’s disease , 2017, Redox biology.

[24]  Kiwon Jung,et al.  Beneficial effects of Panax ginseng for the treatment and prevention of neurodegenerative diseases: past findings and future directions , 2017, Journal of ginseng research.

[25]  K. Caldecott,et al.  Nonsyndromic cerebellar ataxias associated with disorders of DNA single-strand break repair. , 2018, Handbook of clinical neurology.

[26]  Karsten Melcher,et al.  Amyloid beta: structure, biology and structure-based therapeutic development , 2017, Acta Pharmacologica Sinica.

[27]  K. Vossel,et al.  Epileptic activity in Alzheimer's disease: causes and clinical relevance , 2017, The Lancet Neurology.

[28]  A. Al-Chalabi,et al.  What causes amyotrophic lateral sclerosis? , 2017, F1000Research.

[29]  J. Frydman,et al.  Protein misfolding in neurodegenerative diseases: implications and strategies , 2017, Translational Neurodegeneration.

[30]  Norm Allaire,et al.  SMN deficiency in severe models of spinal muscular atrophy causes widespread intron retention and DNA damage , 2017, Proceedings of the National Academy of Sciences.

[31]  Hong Qing,et al.  Epigenetics in Alzheimer’s Disease: Perspective of DNA Methylation , 2017, Molecular Neurobiology.

[32]  D. Averill-Bates,et al.  Activation of apoptosis signalling pathways by reactive oxygen species. , 2016, Biochimica et biophysica acta.

[33]  Shengdi Chen,et al.  Oxidative stress: A major pathogenesis and potential therapeutic target of antioxidative agents in Parkinson’s disease and Alzheimer’s disease , 2016, Progress in Neurobiology.

[34]  M. Montazer,et al.  Encapsulation of Aloe Vera extract into natural Tragacanth Gum as a novel green wound healing product. , 2016, International journal of biological macromolecules.

[35]  R. Patnaik,et al.  Exploring neuroprotective potential of Withania somnifera phytochemicals by inhibition of GluN2B-containing NMDA receptors: An in silico study. , 2016, Medical hypotheses.

[36]  M. Kamal,et al.  In Silico Analysis of Green Tea Polyphenols as Inhibitors of AChE and BChE Enzymes in Alzheimer's Disease Treatment. , 2016, CNS & neurological disorders drug targets.

[37]  H. Mitsumoto,et al.  Potential Environmental Factors in Amyotrophic Lateral Sclerosis. , 2015, Neurologic clinics.

[38]  E. Carro,et al.  Chitosan coated nanostructured lipid carriers for brain delivery of proteins by intranasal administration. , 2015, Colloids and surfaces. B, Biointerfaces.

[39]  Mark E. Davis,et al.  Increased brain uptake of targeted nanoparticles by adding an acid-cleavable linkage between transferrin and the nanoparticle core , 2015, Proceedings of the National Academy of Sciences.

[40]  M. Kim,et al.  Melatonin ameliorates amyloid beta‐induced memory deficits, tau hyperphosphorylation and neurodegeneration via PI3/Akt/GSk3β pathway in the mouse hippocampus , 2015, Journal of pineal research.

[41]  Simon C. Dyall,et al.  Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA , 2015, Front. Aging Neurosci..

[42]  D. Klenerman,et al.  Lipid peroxidation is essential for α‐synuclein‐induced cell death , 2015, Journal of neurochemistry.

[43]  M. Cheetham,et al.  The role of HSP70 and its co-chaperones in protein misfolding, aggregation and disease. , 2015, Sub-cellular biochemistry.

[44]  M. Ciriolo,et al.  Glutathione: new roles in redox signaling for an old antioxidant , 2014, Front. Pharmacol..

[45]  Linqi Shi,et al.  Maintenance of amyloid β peptide homeostasis by artificial chaperones based on mixed-shell polymeric micelles. , 2014, Angewandte Chemie.

[46]  S. Vinogradov,et al.  Targeted Nanogel Conjugate for Improved Stability and Cellular Permeability of Curcumin: Synthesis, Pharmacokinetics, and Tumor Growth Inhibition , 2014, Molecular pharmaceutics.

[47]  L. Tsai,et al.  DNA Damage and Its Links to Neurodegeneration , 2014, Neuron.

[48]  D. Turnbull,et al.  Ageing and Parkinson's disease: Why is advancing age the biggest risk factor?☆ , 2014, Ageing Research Reviews.

[49]  S. Ferreira,et al.  How does brain insulin resistance develop in Alzheimer's disease? , 2014, Alzheimer's & Dementia.

[50]  J. Walton.  Chronic aluminum intake causes Alzheimer's disease: applying Sir Austin Bradford Hill's causality criteria. , 2014, Journal of Alzheimer's disease : JAD.

[51]  Feng Gao,et al.  A novel lactoferrin-modified β-cyclodextrin nanocarrier for brain-targeting drug delivery. , 2013, International journal of pharmaceutics.

[52]  D. Hernandez,et al.  A dominant mutation in FBXO38 causes distal spinal muscular atrophy with calf predominance. , 2013, American journal of human genetics.

[53]  A. Nath,et al.  Retroviruses and amyotrophic lateral sclerosis. , 2013, Antiviral research.

[54]  J. Brodsky,et al.  Synthesis and initial evaluation of YM-08, a blood-brain barrier permeable derivative of the heat shock protein 70 (Hsp70) inhibitor MKT-077, which reduces tau levels. , 2013, ACS chemical neuroscience.

[55]  J. Veltman,et al.  Mutations in BICD2, which encodes a golgin and important motor adaptor, cause congenital autosomal-dominant spinal muscular atrophy. , 2013, American journal of human genetics.

[56]  D. Standaert,et al.  MHCII Is Required for α-Synuclein-Induced Activation of Microglia, CD4 T Cell Proliferation, and Dopaminergic Neurodegeneration , 2013, The Journal of Neuroscience.

[57]  S. Bahmanpour,et al.  Neuroprotective Effects of NMDA and Group I Metabotropic Glutamate Receptor Antagonists Against Neurodegeneration Induced by Homocysteine in Rat Hippocampus: In Vivo Study , 2013, Journal of Molecular Neuroscience.

[58]  J. Chen,et al.  Cholesterol efflux is differentially regulated in neurons and astrocytes: implications for brain cholesterol homeostasis. , 2013, Biochimica et biophysica acta.

[59]  A. Pestronk,et al.  Mutations in the tail domain of DYNC1H1 cause dominant spinal muscular atrophy , 2012, Neurology.

[60]  L. Stefanis.  α-Synuclein in Parkinson's disease. , 2012, Cold Spring Harbor perspectives in medicine.

[61]  S. Leurgans,et al.  Cerebrovascular Disease Pathology and Parkinsonian Signs in Old Age , 2011, Stroke.

[62]  Claudia Martini,et al.  In silico identification of new ligands for GPR17: a promising therapeutic target for neurodegenerative diseases , 2011, J. Comput. Aided Mol. Des..

[63]  P. Wong,et al.  Amyloid precursor protein processing and Alzheimer's disease. , 2011, Annual review of neuroscience.

[64]  A. Koeppen.  Friedreich's ataxia: Pathology, pathogenesis, and molecular genetics , 2011, Journal of the Neurological Sciences.

[65]  J. Burgos,et al.  Statins as neuroprotectants: a comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. , 2011, Journal of Alzheimer's disease : JAD.

[66]  Pamela A McCombe,et al.  Effects of gender in amyotrophic lateral sclerosis. , 2010, Gender medicine.

[67]  W. Chingwaru,et al.  The Role of Functional Foods, Nutraceuticals, and Food Supplements in Intestinal Health , 2010, Nutrients.

[68]  G. Levy,et al.  The relationship of Parkinson disease with aging. , 2007, Archives of neurology.

[69]  K. Akiyoshi,et al.  Inhibition of the formation of amyloid β‐protein fibrils using biocompatible nanogels as artificial chaperones , 2006, FEBS letters.

[70]  Todd R. Flower,et al.  α-Synuclein, oxidative stress and apoptosis from the perspective of a yeast model of Parkinson's disease , 2006 .

[71]  Todd R. Flower,et al.  alpha-Synuclein, oxidative stress and apoptosis from the perspective of a yeast model of Parkinson's disease. , 2006, FEMS yeast research.

[72]  M. Youdim,et al.  Novel multifunctional neuroprotective iron chelator‐monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition , 2005, Journal of neurochemistry.

[73]  M. Hayden,et al.  Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[74]  F. Urano,et al.  Amyloid beta induces neuronal cell death through ROS-mediated ASK1 activation. , 2005, Cell death and differentiation.

[75]  F. Urano,et al.  Amyloid β induces neuronal cell death through ROS-mediated ASK1 activation , 2005, Cell Death and Differentiation.

[76]  M. Mayer,et al.  Hsp70 chaperones: Cellular functions and molecular mechanism , 2005, Cellular and Molecular Life Sciences.

[77]  D. B. Min,et al.  Reactive Oxygen Species, Aging, and Antioxidative Nutraceuticals. , 2004, Comprehensive reviews in food science and food safety.

[78]  M. Vila,et al.  Series Introduction: Neurodegeneration: What is it and where are we? , 2003 .

[79]  J. Langston,et al.  Environmental Risk Factors and Parkinson's Disease: Selective Degeneration of Nigral Dopaminergic Neurons Caused by the Herbicide Paraquat , 2002, Neurobiology of Disease.

[80]  J. Olney,et al.  Ethanol-induced apoptotic neurodegeneration in the developing C57BL/6 mouse brain. , 2002, Brain research. Developmental brain research.

[81]  S. Paul,et al.  Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[82]  J..  Neurodegenerative Diseases , 1996, GWUMC Department of Biochemistry and Molecular Biology Annual Spring Symposia.